ALVO (Alvotech) Short-Term Debt to Capital

Alvotech (ALVO) relies on the development of biosimilars for long-term markets, where inclusion in government procurement registries ensures multi-year demand. This price trend shown below with the 0.00 indicator complements the picture of a stable cash inflow from the sale of approved drugs. However, Alvotech (ALVO) faces intense pressure from original brands and price wars over the right to dismantle third-party patent monopolies.

To objectively assess the stability of Alvotech (ALVO), a portfolio manager must analyze the ratio of liabilities maturing within one year to equity, which determines liquidity risk amid rising interest rates. By examining the history of short-term borrowed capital relative to equity, an investor can identify the company's financial cushion for the commercialization of biosimilars, where low dependence on short-term debt ensures independent revenue growth regardless of macroeconomic cycles.